The Pentagon has issued new clinical practice guidelines requiring mandatory testosterone deficiency screening for all male service members over age 30, two weeks after similar guidance was abruptly removed from a Department of Defense website.
The reinstated policy represents a significant expansion of military health monitoring, addressing what defense officials describe as a critical readiness concern that has gained particular attention within the special operations community.
Chief Pentagon spokesman Sean Parnell stated that the guidance “addresses male testosterone deficiency, establishing uniform screening and treatment pathways across the DHA enterprise and assigning responsibility for compliance.” He emphasized that by proactively identifying and treating suboptimal hormone levels, the Department continues to invest in warfighter health, strengthen performance, and maximize force readiness.
The temporary removal of the original guidelines two weeks ago raised questions within military circles. A senior adviser to Defense Secretary Pete Hegseth explained that the documents had been posted inadvertently and were considered draft materials at the time. No additional explanation was provided for the rescission.
Under the newly published clinical practice guidelines, all male service members over 30 will undergo structured symptom and risk assessments. Service members under 30 may request screening. The testing protocol requires testosterone levels to be measured on two separate days during morning hours while service members are fasting. A repeat blood draw will include an LH/FSH panel measuring luteinizing hormone and follicle-stimulating hormone, two reproductive hormones produced by the pituitary gland.
When total testosterone levels fall within normal range, additional testing will measure free testosterone levels. Total testosterone represents the entire amount circulating in the body, both bound and unbound to proteins, while free testosterone refers only to biologically active hormone not bound to proteins.
The Pentagon indicated that comparable guidance for female service members remains under review and will be posted upon approval. The earlier, rescinded version had included provisions for screening female personnel regarding fatigue and disrupted menstrual cycles potentially associated with hormonal dysregulation.
Earlier this year, Secretary Hegseth announced that annual testosterone testing would become standard practice for all troops, marking a notable policy shift on an emerging health concern.
Low testosterone levels have become particularly worrisome within special operations forces, where sustained high-stress operations and extreme physical demands, combined with inadequate caloric intake, may negatively impact hormone production. Research into these correlations remains ongoing.
According to the American Urological Association, between 4 million and 13.8 million American men suffered from testosterone deficiency as of 2023. The full scope of the condition remains uncertain, complicated by varying diagnostic thresholds used across the medical community.
The new screening requirements reflect growing recognition within military leadership that hormonal health directly affects combat readiness and operational effectiveness. By establishing uniform screening protocols across all service branches, the Defense Department aims to identify and address deficiencies before they compromise individual performance or unit capability.
Related: Moderna’s mRNA Flu Shot Approved for Americans 50 and Older
